Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle

Journal of Clinical Oncology

Volumn 28, Issue 36, 2010, Pages 5280-5286

  Jensen, Søren Astrup ^a   Hasbak, Philip ^a   Mortensen, Jann ^a   Sørensen, Jens Benn ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; FLUOROURACIL; FOLINIC ACID; LACTIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COLORECTAL CANCER; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PATHOPHYSIOLOGY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOISOTOPE VENTRICULOGRAPHY; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LACTIC ACID; LEUCOVORIN; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79951907915     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.3953     Document Type: Article

References (42)

1. Jensen SA, Sørensen JB: Risk factors and prevention of Cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58: 487-493, 2006 (Pubitemid 43999797)
2. Wacker A, Lersch C, Scherpinski U, et al: High incidence of angina pectoris in patients treated with 5-fluorouracil: A planned surveillance study with 102 patients. Oncology 65:108-112, 2003 (Pubitemid 37025969)
3. Tsavaris N, Kosmas C, Vadiaka M, et al: Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy: A survey of 427 patients. Med Sci Monit 8:PI51-PI57, 2002
4. Schöber C, Papageorgiou E, Harstrick A, et al: Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 72:2242-2247, 1993 (Pubitemid 23280155)
5. de Forni M, Malet-Martino MC, Jaillais P, et al: Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study. J Clin Oncol 10:1795-1801, 1992 (Pubitemid 23059959)
6. Akhtar SS, Salim KP, Bano ZA: Symptomatic Cardiotoxicity with high-dose 5-fluorouracil infusion: A prospective study. Oncology 50:441-444, 1993 (Pubitemid 23323713)
7. Matsubara I, Kamiya J, Imai S: Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 30:871-879, 1980 (Pubitemid 11162895)
8. Millart H, Brabant L, Lorenzato M, et al: The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart. Anticancer Res 12:571-576, 1992
9. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, et al: Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 25:305-309, 2006 (Pubitemid 44064964)
10. Lahiri A, Rodrigues EA, Carboni GP, et al: Effects of long-term treatment with calcium antagonists on left ventricular diastolic function in stable angina and heart failure. Circulation 81:III130-III138, 1990
11. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al: Prospective evaluation of early cardiac damage inducedbyepirubicin-containingadjuvantchemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746-2753, 2001 (Pubitemid 32441381)
12. Petit T: Anthracycline-induced Cardiotoxicity [in French]. Bull Cancer 91:159-165, 2004 (suppl 3)
13. Vesely DL: Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? Clin Exp Pharmacol Physiol 33:169-176, 2006
14. Hall C: NT-ProBNP: The mechanism behind the marker. J Card Fail 11:S81-S83, 2005
15. Perik PJ, Van der Graaf WT, De Vries EG, et al: Circulating apoptotic proteins are increased in longterm disease-free breast cancer survivors. Acta Oncol 45:175-183, 2006
16. Kuittinen T, Jantunen E, Vanninen E, et al: Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Eur J Haematol 77:120-127, 2006
17. Perik PJ, Lub-De Hooge MN, Gietema JA, et al: Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24:2276-2282, 2006 (Pubitemid 46630657)
18. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension: Guidelines Subcommittee. J Hypertens 17:151-183, 1999
19. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 30:S42-S47, 2007 (suppl 1)
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
21. Dignam JJ, Polite BN, Yothers G, et al: Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 98:1647-1654, 2006 (Pubitemid 44811647)
22. Troughton RW, Richards AM, Yandle TG, et al: The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med 39:242-260, 2007 (Pubitemid 46897664)
23. Ballard HS, Bottino G, Bottino J: Ondansetron and chest pain. Lancet 340:1107, 1992
24. Ndrepepa G, Braun S, Mehilli J, et al: A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. Clin Res Cardiol 96:30-37, 2007 (Pubitemid 46175368)
25. Navarro Estrada JL, Rubinstein F, Bahit MC, et al: NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes. Am Heart J 151:1093-1097, 2006
26. Weber M, Kleine C, Keil E, et al: Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95:270-280, 2006
27. Riezebos RK, Ronner E, de Boer BA, et al: Dynamics in N-terminal pro-brain natriuretic peptide concentration in patients with non-ST-elevation acute coronary syndrome. Am Heart J 150:1255-1259, 2005 (Pubitemid 41773532)
28. Jernberg T, James S, Lindahl B, et al: NTProBNP in non-ST-elevation acute coronary syndrome. J Card Fail 11:S54-S58, 2005
29. Staub D, Jonas N, Zellweger MJ, et al: Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. Am J Med 118:1287, 2005
30. Wolber T, Maeder M, Rickli H, et al: N-terminal pro-brain natriuretic peptide used for the prediction of coronary artery stenosis. Eur J Clin Invest 37:18-25, 2007 (Pubitemid 44934768)
31. Kouloubinis A, Kaklamanis L, Ziras N, et al: ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. Int J Cardiol 122:195-201, 2007 (Pubitemid 47615179)
32. Nousiainen T, Vanninen E, Jantunen E, et al: Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin Sci (Lond) 101:601-607, 2001 (Pubitemid 33135340)
33. Snowden JA, Hill GR, Hunt P, et al: Assessment of Cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 26:309-313, 2000 (Pubitemid 30614412)
34. Pascual-Figal DA, Antolinos MJ, Bayes-Genis A, et al: B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans. Heart 93:1077-1080, 2007 (Pubitemid 47310986)
35. Holubec L Jr, Topolcan O, Finek J, et al: Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients: A pilot study. Anticancer Res 27:1883-1886, 2007
36. Kondo K, Fujiwara M, Murase M, et al: Severe acute metabolic acidosis and Wernicke's encephalopathy following chemotherapy with 5-fluorouracil and cisplatin: Case report and review of the literature. Jpn J Clin Oncol 26:234-236, 1996 (Pubitemid 126474685)
37. Nio Y, Tseng CC, Shiraishi T, et al: A phase II study of 5-fluorouracil, cisplatin, and 4′-epirubicin in the treatment of advanced solid cancers. Am J Clin Oncol 16:96-101, 1993 (Pubitemid 23109713)
38. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091, 2006 (Pubitemid 46622283)
39. Høilund-Carlsen PF, Lauritzen SL, Marving J, et al: The reliability of measuring left ventricular ejection fraction by radionuclide cardiography: Evaluation by the method of variance components. Br Heart J 59:653-662, 1988
40. Miwa K, Ishii K, Makita T, et al: Effects of postischemic regional left ventricular diastolic wall motion abnormalities or delayed relaxation following coronary vasospasm on global diastolic function. Circ J 69:439-445, 2005
41. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237, 1989 (Pubitemid 19114713)
42. Luchner A, Hengstenberg C, Löwel H, et al: Effect of compensated renal dysfunction on approved heart failure markers: Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 46:118-123, 2005 (Pubitemid 40946501)